Ovarian Transposition Before Radiotherapy in Cervical Cancer Patients: Functional Outcome and the Adequate Dose Constraint

Overview

Journal Radiat Oncol

Publisher Biomed Central

Specialties Oncology
Radiology

Date 2019 Jun 12

PMID 31182114

Citations 14

Authors

Lina Yin

Saiquan Lu

Jun Zhu

Weiling Zhang

Guihao Ke

Affiliations

Soon will be listed here.

Abstract

Background: The data regarding a transposed ovary in intensity-modulated radiotherapy (IMRT) are not sufficient. Here we aim to investigate the adequate dose constraint of ovarian transposition before radiotherapy in cervical cancer patients.

Methods: This was a retrospective analysis of 118 patients with cervical cancer who received a radical hysterectomy and ovarian transposition before pelvic irradiation from April 2012 to July 2017. A total of 105 patients underwent IMRT with a limited radiation dose to the ovaries; 48 of these patients received unilateral ovary limitation, while 57 received bilateral ovary limitations. Patient follow up regarding sex hormone levels (estrogen [E2], follicle stimulating hormone [FSH]) and menopausal symptoms was completed one year after their radiation therapy.

Results: A total of 41 out of 105 patients (39.0%) who underwent IMRT with a limited radiation dose to the ovaries preserved their normal ovarian function. The cutoff dose of comparatively lower side ovarian maximum dose was 9.985Gy and the cutoff of mean dose was 5.32Gy. The optimal dose-volume constrains to ovaries was V5.5 < 29.65%. Age ≤ 38 (P = 0.001) was an independent predictors of ovarian function, while limited ovarian side numbers were excluded.

Conclusion: Using IMRT, preservation of ovarian function was possible when the limited dose was as low as possible to the ovaries regardless of bilateral or unilateral limitation to the ovaries. The ovarian maximum dose of less than 9.985Gy, the mean dose less than 5.32Gy and V5.5 < 29.65% could be better at preventing ovarian dysfunction. Patients younger than 38 years old were more likely to keep normal ovarian function while limited ovarian side numbers did not appear to exert an obvious effect.

Citing Articles

Determination of ovarian transposition through prediction of postoperative adjuvant therapy in young patients with early stage cervical cancer undergoing surgery: a Korean multicenter retrospective study (KGOG 1042).

Hwang W, Choi C, Kim K, Kim M, Lim M, Lee B Obstet Gynecol Sci. 2024; 67(3):296-303.

PMID: 38484700 PMC: 11099092. DOI: 10.5468/ogs.23291.

Impact of ovary-sparing treatment planning on plan quality, treatment time and gamma passing rates in intensity-modulated radiotherapy for stage I/II cervical cancer.

Huang Y, Qin T, Yang M, Liu Z Medicine (Baltimore). 2023; 102(50):e36373.

PMID: 38115303 PMC: 10727547. DOI: 10.1097/MD.0000000000036373.

Preparation and Characterization Evaluation of Poly(L-Glutamic Acid)--Methoxy Poly(Ethylene Glycol)/Combretastatin A4/BLZ945 Nanoparticles for Cervical Cancer Therapy.

Guo D, Huang Y, Wang K, Yang C, Ma L, Zhang Y Int J Nanomedicine. 2023; 18:6901-6914.

PMID: 38026524 PMC: 10676729. DOI: 10.2147/IJN.S441131.

Successful Pre-Treatment Ovarian Fresh Tissue Transplantation in a Cervical Cancer Patient Undergoing Radiation Therapy: A Case Report.

Bertolazzi M, Genta M, Carvalho F, Baracat E, Carvalho J Cureus. 2023; 15(8):e43472.

PMID: 37711948 PMC: 10499302. DOI: 10.7759/cureus.43472.

Fertility-sparing options for cancer patients.

Alur-Gupta S, Fruchtman H, Paroder V Abdom Radiol (NY). 2023; 48(5):1618-1628.

PMID: 36884058 DOI: 10.1007/s00261-023-03839-8.

References

Morris M, Eifel P, Lu J, Grigsby P, Levenback C, STEVENS R . Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999; 340(15):1137-43. DOI: 10.1056/NEJM199904153401501. View

Morice P, Juncker L, Rey A, Haie-Meder C, Castaigne D . Ovarian transposition for patients with cervical carcinoma treated by radiosurgical combination. Fertil Steril. 2000; 74(4):743-8. DOI: 10.1016/s0015-0282(00)01500-4. View

Buekers T, Anderson B, Sorosky J, Buller R . Ovarian function after surgical treatment for cervical cancer. Gynecol Oncol. 2001; 80(1):85-8. DOI: 10.1006/gyno.2000.6039. View

Bisharah M, Tulandi T . Laparoscopic preservation of ovarian function: an underused procedure. Am J Obstet Gynecol. 2003; 188(2):367-70. DOI: 10.1067/mob.2003.38. View

Farber L, Ames J, Rush S, Gal D . Laparoscopic ovarian transposition to preserve ovarian function before pelvic radiation and chemotherapy in a young patient with rectal cancer. MedGenMed. 2005; 7(1):66. PMC: 1681369. View

Huang K, Lee C, Tsai C, Han C, Hwang L . A new approach for laparoscopic ovarian transposition before pelvic irradiation. Gynecol Oncol. 2007; 105(1):234-7. DOI: 10.1016/j.ygyno.2006.12.001. View

Pahisa J, Martinez-Roman S, Martinez-Zamora M, Torne A, Caparros X, Sanjuan A . Laparoscopic ovarian transposition in patients with early cervical cancer. Int J Gynecol Cancer. 2008; 18(3):584-9. DOI: 10.1111/j.1525-1438.2007.01054.x. View

Martin K, Manson J . Approach to the patient with menopausal symptoms. J Clin Endocrinol Metab. 2008; 93(12):4567-75. DOI: 10.1210/jc.2008-1272. View

Dursun P, Ayhan A, Yanik F, Kuscu E . Ovarian transposition for the preservation of ovarian function in young patients with cervical carcinoma. Eur J Gynaecol Oncol. 2009; 30(1):13-5. View

10.

Bentzen S, Constine L, Deasy J, Eisbruch A, Jackson A, Marks L . Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010; 76(3 Suppl):S3-9. PMC: 3431964. DOI: 10.1016/j.ijrobp.2009.09.040. View

11.

Chambers S, Chambers J, Kier R, Peschel R . Sequelae of lateral ovarian transposition in irradiated cervical cancer patients. Int J Radiat Oncol Biol Phys. 1991; 20(6):1305-8. DOI: 10.1016/0360-3016(91)90242-v. View

12.

Chambers S, Chambers J, Holm C, Peschel R, Schwartz P . Sequelae of lateral ovarian transposition in unirradiated cervical cancer patients. Gynecol Oncol. 1990; 39(2):155-9. DOI: 10.1016/0090-8258(90)90424-j. View

13.

Cai H, Liu X, Huang Y, Li X, Lie D, Zhou Q . Trends in cervical cancer in young women in Hubei, China. Int J Gynecol Cancer. 2011; 20(7):1240-3. DOI: 10.1111/igc.0b013e3181ecec79. View

14.

Hwang J, Yoo H, Park S, Lim M, Seo S, Kang S . Association between the location of transposed ovary and ovarian function in patients with uterine cervical cancer treated with (postoperative or primary) pelvic radiotherapy. Fertil Steril. 2012; 97(6):1387-93.e1-2. DOI: 10.1016/j.fertnstert.2012.02.052. View

15.

Mascarenhas-Melo F, Sereno J, Teixeira-Lemos E, Ribeiro S, Rocha-Pereira P, Cotterill E . Markers of increased cardiovascular risk in postmenopausal women: focus on oxidized-LDL and HDL subpopulations. Dis Markers. 2013; 35(2):85-96. PMC: 3774979. DOI: 10.1155/2013/724706. View

16.

An Y, Qiao Z, Zou M, Yu J . [Dynamic monitoring on ovarian function among patients having had cervical squamous cell carcinoma transposition surgery]. Zhonghua Liu Xing Bing Xue Za Zhi. 2014; 35(1):85-7. View

17.

Soda I, Ishiyama H, Ono S, Takenaka K, Arai M, Arai T . Assessment of transposed ovarian movement: how much of a safety margin should be added during pelvic radiotherapy?. J Radiat Res. 2015; 56(2):354-9. PMC: 4380061. DOI: 10.1093/jrr/rru116. View

18.

Owens S, ROBERTS W, Fiorica J, Hoffman M, Lapolla J, Cavanagh D . Ovarian management at the time of radical hysterectomy for cancer of the cervix. Gynecol Oncol. 1989; 35(3):349-51. DOI: 10.1016/0090-8258(89)90077-2. View

19.

Motoki Y, Mizushima S, Taguri M, Takahashi K, Asano R, Kato H . Increasing trends in cervical cancer mortality among young Japanese women below the age of 50 years: an analysis using the Kanagawa population-based Cancer Registry, 1975-2012. Cancer Epidemiol. 2015; 39(5):700-6. DOI: 10.1016/j.canep.2015.08.001. View

20.

Moon E, Oh C, Won Y, Lee J, Jung K, Cho H . Trends and Age-Period-Cohort Effects on the Incidence and Mortality Rate of Cervical Cancer in Korea. Cancer Res Treat. 2016; 49(2):526-533. PMC: 5398407. DOI: 10.4143/crt.2016.316. View